Areva in Bethesda, MD, is a pioneering company focused on developing Targeted Alpha Therapy against cancer. With a mission to make successful therapy a reality, Orano Med utilizes the unique properties of lead-212, a rare alpha-emitting radioisotope, to create potent therapeutic payloads for combating cancer cells.
With a team of 100 employees in France and the United States, Orano Med boasts two preclinical laboratories, an industrial production platform for lead-212, ongoing clinical trials, and 12 patented inventions. Positioned at the forefront of innovation, the company is driving growth in the radioligand therapy market and shaping the future of cancer treatment.
Generated from the website